3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
123
Carcinoma, Hepatocellular
72
Neoplasms
48
Breast Neoplasms
48
Small Cell Lung Carcinoma
46
Lung Neoplasms
42
Triple Negative Breast Neoplasms
40
Colorectal Neoplasms
39
Melanoma
35
Urinary Bladder Neoplasms
33
Neoplasm Metastasis
31
Carcinoma, Transitional Cell
31
Carcinoma, Renal Cell
29
Ovarian Neoplasms
20
Uterine Cervical Neoplasms
19
Stomach Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
17
Head and Neck Neoplasms
15
Prostatic Neoplasms
13
Liver Neoplasms
13
Glioblastoma
12
Solid Tumors
11
Recurrence
11
Sarcoma
10
Esophageal Neoplasms
10
Pancreatic Neoplasms
9
Lymphoma
9
Endometrial Neoplasms
9
Mesothelioma, Malignant
8
Kidney Neoplasms
8
Interventions
pemigatinib
6
infigratinib
3
erdafitinib
2
derazantinib
2
Rogaratinib
2
pembrolizumab
1
lenvatinib
1
exemestane
1
brivanib
1
atezolizumab
1
Rabeprazole
1
Irinotecan
1
INCB 54828-101
1
Gemcitabine
1
Fulvestrant
1
E-3810
1
Drug Combinations
1
Carboplatin
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Acrocephalosyndactylia
×
atezolizumab
×
Clear all
NCT04045613
2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2
Completed
95 enrolled
25 charts